View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
January 18, 2022

Sensorion’s sudden sensorineural hearing loss asset fails Phase II test

The asset failed to meet the primary goal of 15 decibels, a substantial improvement in pure tone audiometry in the affected ear from baseline.

Sensorion announced that the Phase II AUDIBLE-S clinical trial of its drug candidate SENS-401 (Arazasetron) to treat sudden sensorineural hearing loss (SSNHL) failed to meet the primary goal.

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

The asset failed to meet the primary endpoint of 15 decibels (dB), a substantial improvement in pure tone audiometry (PTA) in the affected ear from baseline versus placebo after four weeks of treatment.

That said, a sub-assessment in subjects with hearing threshold greater than or equal to 80dB, indicating severe hearing loss, demonstrated an enhanced response versus placebo at the two drug doses. 

This subset accounted for 30% of the total trial population. 

In the trial, SENS-401 was demonstrated to be safe and well-tolerated. Furthermore, the findings validate the data from the preclinical model of severe noise-induced hearing loss, the company said.

Sensorion will continue to analyse results from the trial, with the secondary endpoints data anticipated in mid-March this year. 

SENS-401 is a small molecule that can be administered orally or through an injection. It is intended to offer protection and preserve the inner ear tissue from damage. The tissue damage could lead to progressive or sequelar hearing impairment. 

The multicentre, double-blind, randomised, placebo-controlled trial enrolled 115 patients.

Subjects with severe or profound SSNHL were enrolled within 96 hours after the development of a sudden and severe hearing loss. 

They were categorised to receive either 29mg and 43.5mg twice the daily oral dose of SENS-401 or a placebo. 

Sensorion CMO Géraldine Honnet said: “We are encouraged by the SENS-401 activity data that showed a continuous improvement from day seven until day 28. 

“We will review the full data as soon as possible and explore in particular the PTA comparisons at day 84 and the other secondary endpoints in the trial to determine the best development path for SENS-401.”

In February 2020, Sensorion obtained approval from the Independent Ethics Committee of Strasbourg in France to include military sites in the Phase II trial of SENS-401 for treating SSNHL.

Related Companies

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena